Last reviewed 2026-04-23 · How we verify

Inpegsomatropin Injection

Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.

Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults.

At a glance

Mechanism of action

Inpegsomatropin is a pegylated recombinant human growth hormone designed for extended half-life and reduced injection frequency. It activates growth hormone receptors on target tissues, stimulating insulin-like growth factor-1 (IGF-1) production and promoting linear growth, protein synthesis, and lipolysis. The pegylation modification allows for less frequent dosing compared to standard somatropin.

Approved indications

• Growth hormone deficiency in children
• Growth hormone deficiency in adults

Common side effects

• Injection site reactions
• Headache
• Arthralgia
• Carpal tunnel syndrome
• Fluid retention

Key clinical trials

• The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (PHASE3)
• The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Inpegsomatropin Injection CI brief — competitive landscape report
• Inpegsomatropin Injection updates RSS · CI watch RSS
• Xiamen Amoytop Biotech Co., Ltd. portfolio CI